Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
Conditions Studied
Interventions
- DRUG 1.0% IP-001 for Injection
Study Locations (16)
Other
- Institut Bergonie — Bordeaux
- Hospitalier Pitie-Salpetriere — Paris
- Hôpital Foch — Suresnes
- Institut Gustave Roussy — Villejuif
- Johann Wolfgang Goethe-Univresitat Frankfurt/Main — Frankfurt
- SLK-Kliniken Heilbronn GmbH — Heilbronn
- Munchen Klinik Bogenhausen — Munich
- IOSI Ospedale San Giovanni Bellinzona — Bellinzona
- Inselspital Universitatsspital, Bern — Bern
- Kantonsspital Graubunden — Chur
- Kantonsspital St. Gallen — Sankt Gallen
- University College London Hospitals — London
- Churchill Hospital — Oxford
Florida
- Miami Cardiac & Vascular Institute — Coral Gables
Kentucky
- University of Louisville Physicians, PSC — Louisville
Oklahoma
- Stephenson Cancer Center — Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2025-02 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05688280
The ClinicalTrials.gov registry entry for NCT05688280 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunophotonics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention — of which 1.0% IP-001 for Injection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05688280 reports 16 study locations spanning 4 distinct geographic areas — top geographies include Other, Florida, Kentucky. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05688280 about?
NCT05688280 is a clinical study titled "Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS". The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
What is the current status of trial NCT05688280?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-11-29. Estimated completion is 2025-02.
What conditions does trial NCT05688280 study?
This clinical trial studies the following conditions: Colon Cancer, Soft Tissue Sarcoma, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05688280?
The interventions under investigation include: 1.0% IP-001 for Injection (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05688280?
This trial is sponsored by Immunophotonics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05688280 being conducted?
This trial has 16 study locations across Florida, Kentucky, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.